Tempus AI, Inc. (NASDAQ: TEM), a technology company at the forefront of using artificial intelligence to advance precision medicine, has announced the launch of Paige Predict, a new AI-powered solution for digital pathology. This follows Tempus’s acquisition of Paige in 2025 and marks a significant step in integrating advanced AI capabilities into clinical workflows. Paige Predict is designed to analyze hematoxylin and eosin (H&E) whole slide images to predict the presence or absence of clinically relevant biomarkers and oncogenic molecular pathways. The tool enables physicians to make more informed testing decisions, especially when tissue samples are limited or insufficient for traditional molecular profiling. In cases where a biopsy is deemed “quantity not sufficient” (QNS), patients often face delays of days or weeks while waiting for repeat procedures or alternative testing. Paige Predict helps reduce this uncertainty by providing actionable insights from a single H&E slide, allowing clinicians to prioritize the most effective confirmatory tests and maximize the chance of obtaining meaningful results before tissue is exhausted. The solution leverages Tempus and Paige’s combined digital pathology platform and proprietary AI models. It is trained on a multimodal dataset of over 200,000 de-identified patient cases, integrating data from both organizations. The model has been rigorously validated across diverse and large-scale datasets, including a major cohort from Tempus, demonstrating strong performance, generalizability, and robustness. Paige Predict can assess the likelihood of 123 biomarkers and molecular pathways across 16 cancer types, including non-small cell lung cancer (NSCLC), prostate, breast, pancreatic, and colorectal cancers. Results are automatically included in clinical reports delivered to ordering physicians, streamlining integration into existing care pathways. Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus, said, “Tissue can be scarce, but insights don’t have to be. Paige Predict overcomes one of the biggest barriers in next-generation sequencing by delivering critical information to guide testing decisions when full molecular profiling isn’t possible. This is a defining moment for Tempus and Paige as we continue to advance digital pathology and bring transformative technology to patient care.” Tempus continues to build on its mission to improve precision medicine through AI. With one of the world’s largest collections of multimodal clinical and genomic data, the company is developing tools that learn and improve over time, enabling physicians to deliver personalized care. The goal is to ensure every patient benefits from the collective knowledge of previous cases. The company notes that this announcement includes forward-looking statements about the potential benefits of Paige Predict in clinical practice. These statements involve risks and uncertainties, including those related to regulatory compliance, competition, intellectual property, financial performance, and the evolving landscape of AI in healthcare. Tempus cautions that actual results may differ materially and undertakes no obligation to update these statements unless required by law.